clinical trial · NCT07632404
A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
Novo Nordisk A/S·—·enrolling by invitation·n = 214
Diabetes Mellitus, Type 2Insulin icodec
brief summary
The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 2 diabetes (T2D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.
started
May 28, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Sep 18, 2026
official title
A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in Italy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol